Cymabay therapeutics, inc. (CBAY)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Operating activities
Net loss

-102,808

-72,548

-27,557

-26,671

-15,529

-31,917

-10,073

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

572

105

35

29

22

18

55

Amortization of notes payable conversion option

-

-

-

-

-

-

10

Non-employee stock-based compensation expense

-

-

-

-

-

8

17

Stock-based compensation expense

9,558

7,013

4,920

2,473

2,487

1,284

875

Accelerated vesting of stock-based compensation expense due to restructuring

910

-

-

-

-

-

-

Amortization of premium on marketable securities

-

-

-

-

511

453

48

Net accretion and amortization of investments in marketable securities

2,237

1,945

199

-125

-228

-198

-47

Non-cash interest associated with debt discount accretion

-

148

437

476

-

-

-

Loss on extinguishment of debt

-

-407

-

-

-

-

-

Change in fair value of warrant liability

-

3,700

5,773

-75

-11,121

7,236

494

Gain on extinguishment of warrant liability

-

422

-

-

-

-

-

Accretion of tenant improvement allowance

-

263

-

-

-

-

-

Loss on sale of property and equipment

-

-

-

-

-

-2

632

Changes in assets and liabilities:
Receivable from collaboration

-

-5,000

5,000

-

-

-

-

Prepaid research and development expenses and other prepaid assets

-8,697

-1,386

-

-

-

-

-

Interest receivable and other current assets

383

178

-

-

-

-

-

Other current assets

-

-

98

-165

-161

-

-

Contract receivables

-

-

-

-

-

101

2

Accrued interest receivable

-

-

-

-

-

68

59

Prepaid expenses

-

-

-161

761

-1,383

1,627

217

Other assets

-2,120

1,646

-120

13

486

-3

216

Accounts payable

530

662

412

-109

-1,077

1,388

40

Accrued restructuring charges

3,193

-

-

-

-

-

-

Accrued liabilities

-669

6,450

1,387

1,015

-46

1,889

499

Accrued interest payable

-

-43

-23

-7

143

107

692

Other liabilities

-

-

-

-

-

13

-36

Net cash used in operating activities

-97,900

-54,936

-19,632

-23,353

-23,324

-21,114

-8,458

Investing activities
Purchases of property and equipment

315

529

27

42

-

103

-

Proceeds from sale of property and equipment

-

-

-

-

-

-

658

Purchases of marketable securities

290,893

276,382

98,385

22,906

42,788

27,334

6,933

Proceeds from maturities of marketable securities

252,881

222,800

30,884

50,076

31,705

10,499

44

Proceeds from sale of marketable securities

3,980

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-34,347

-54,111

-67,528

27,128

-11,083

-16,938

-6,231

Financing activities
Proceeds from issuance of common stock, net of issuance costs

107,746

135,520

100,436

-

25,375

25,430

26,514

Proceeds from issuance of common stock pursuant to equity award plans

386

3,571

2,189

-

-

5

-

Repurchase of preferred stock

-

-

-

-

-

-

3

Proceeds from issuance of common stock upon exercise of warrants

-

2,600

231

-

426

46

-

Proceeds from facility loan

-

-

-

-

9,482

-

4,853

Repayment of facility loan principal

-

6,527

3,137

986

4,756

244

-

Payment of fees to extinguish facility loan

-

126

-

-

-

-

-

Cash provided by financing activities

108,132

134,988

99,719

-986

30,527

25,237

31,364

Net increase in cash and cash equivalents

-24,126

25,941

12,559

2,789

-3,880

-12,815

16,675

Supplemental disclosure
Cash paid for amounts included in the measurement of lease liabilities

628

-

-

-

-

-

-

Cash paid for interest

-

231

666

866

535

435

74

Supplemental non-cash investing and financing activities
Financing costs in accrued expenses

-

-

-

-

-

-

309

Issuance of common stock warrants to lenders

-

-

-

-

-

-

479

Fair value of forward contract

-

-

-

-

-

-

453

Issuance of common stock warrants to lenders

-

-

-

-

258

443

5,493

Conversion of preferred shares into common stock

-

-

-

-

-

-

323,155

Issuance of common stock for debt extinguishment

-

-

-

-

-

-

16,945

Issuance of common stock upon warrant exercises

-

9,379

827

-

1,513

549

-

Operating lease right-of-use assets obtained in exchange for lease liabilities

152

-

-

-

-

-

-

Lessor funded lease incentives included in property and equipment

-

2,256

-

-

-

-

-

Accrued property and equipment

-

156

-

-

-

-

-

Net change in accrued financing costs

-

-

-144

144

-

-

-

Noncash issuance costs incurred in common stock financing

-

-

-

-

-

453

-

Reclassification of incentive awards to equity

-

-

-

-

-

121

-